Genta Reiterates Company Progress and Timelines for Genasense(TM)
BERKELEY HEIGHTS, N.J., Oct 8, 2002 /PRNewswire-FirstCall via COMTEX/ -- Genta
Incorporated (Nasdaq: GNTA) presented an overview of the companies pipeline,
programs and strategic initiatives for future growth yesterday at the UBS
Warburg Life Sciences conference in New York. The presentation included an
update on the continued progress of Genta's lead anticancer compound,
Genasense(TM), along with a comprehensive overview of the current clinical
trials programs.
The Company currently has three randomized clinical trials that employ Genasense
plus chemotherapy in patients with malignant melanoma, multiple myeloma, and
chronic lymphocytic leukemia. Enrollment into these trials remains on track,
consistent with previous guidance. The Company also reiterates its confidence
that a positive result from any one of these trials will enable the Company to
file a New Drug Application (NDA) on schedule by the summer of 2003, consistent
with previous guidance. Genasense has received Orphan Drug designation by the
Food and Drug Administration (FDA) for each of these three indications. The
Company has also received Fast Track designation for melanoma and myeloma.
For a review of the archived audio webcast this presentation please visit:
ubswarburg.com. The audio will be
available for 30 days.
About Genasense
Genasense works by inhibiting the production of Bcl-2, a protein made by cancer
cells that is thought to block chemotherapy-induced cell death. By reducing the
amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of
current anticancer treatments. Genasense is currently in multiple late-stage
randomized clinical trials including malignant melanoma, multiple myeloma,
chronic lymphocytic leukemia (CLL) and non-small cell lung cancer. Genta is also
conducting additional clinical trials in leukemia, lymphoma, and cancers of the
lung, breast, and prostate.
About Genta
Genta Incorporated is a biopharmaceutical company with a diversified product
portfolio that is focused on anticancer therapy. The Company's research platform
is anchored by oligonucleotide chemistry, particularly applications of antisense
and decoy aptamer technology. Genasense(TM), the Company's lead compound, is
being developed in collaboration with Aventis and is currently undergoing
late-stage, Phase 3 clinical testing in several clinical indications. Genta's
pipeline also comprises a portfolio of small molecules, including
gallium-containing compounds and Androgenics compounds for prostate cancer. For
more information about Genta, please visit our website at: genta.com
. |
